SwePub - sökning: onr:"swepub:oai:lup.lub.lu.se:...

Numrering	Referens	Omslagsbild	Hitta
1.	Löhr, J. -M, et al. (författare) Nanoparticles for cancer therapy 2017 Ingår i: Läkartidningen. - : Swedish Medical Association. - 0023-7205 .- 1652-7518. ; 114:27-29 Tidskriftsartikel (refereegranskat)abstract Nanoparticles carry a big promise in oncology, for diagnosis/imaging, therapy, or both (theragnostics). As common in medical history, there is a huge gap between the exciting experimental possibilities and data and clinical studies making use of it. Of the cell-containing nanoparticles, only one formulation using gene-directed enzyme prodrug therapy (GDEPT) with CYP2B1 and ifosfamide was used in early clinical studies. Of the cellfree nanoparticles, some drug-releasing (doxorubicin) ones are in clinical use for trans-arterial chemoembolization (TACE) in liver tumors and metastasis. Using liposomes, both paclitaxel and irinotecan have been used in pancreatic cancer as the model indication. Nanoparticle-albumin-bound paclitaxel (NAB-paclitaxel) has also been developed and is now registered as a drug for first-line therapy of pancreatic cancer, as is the liposomal irinotecan. The novel nanoparticle formulations carry a big promise for even better performance, both in diagnosis and therapy; however, few of these has entered the clinic as of today.

Löhr, J. -M, et al. (författare)
Nanoparticles for cancer therapy
2017
Ingår i: Läkartidningen. - : Swedish Medical Association. - 0023-7205 .- 1652-7518. ; 114:27-29
Tidskriftsartikel (refereegranskat)abstract
- Nanoparticles carry a big promise in oncology, for diagnosis/imaging, therapy, or both (theragnostics). As common in medical history, there is a huge gap between the exciting experimental possibilities and data and clinical studies making use of it. Of the cell-containing nanoparticles, only one formulation using gene-directed enzyme prodrug therapy (GDEPT) with CYP2B1 and ifosfamide was used in early clinical studies. Of the cellfree nanoparticles, some drug-releasing (doxorubicin) ones are in clinical use for trans-arterial chemoembolization (TACE) in liver tumors and metastasis. Using liposomes, both paclitaxel and irinotecan have been used in pancreatic cancer as the model indication. Nanoparticle-albumin-bound paclitaxel (NAB-paclitaxel) has also been developed and is now registered as a drug for first-line therapy of pancreatic cancer, as is the liposomal irinotecan. The novel nanoparticle formulations carry a big promise for even better performance, both in diagnosis and therapy; however, few of these has entered the clinic as of today.

Träfflista för sökning "onr:"swepub:oai:lup.lub.lu.se:71d92a8b-5cdf-4989-ac46-1ef4ee6ee251" "